Chief Executive Officer, Kodiak Sciences
Appears in 1 story
Leading Kodiak toward its first FDA filing
A drug Kodiak Sciences shelved in 2023 after a cataract safety signal is now on track for an FDA filing. The company reported Monday that both its experimental therapies for wet age-related macular degeneration met their primary endpoints against Regeneron's standard-of-care Eylea in the Phase 3 DAYBREAK trial.
Updated 1 hour ago
No stories match your search
Try a different keyword
How would you like to describe your experience with the app today?
